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Strong thrombocytopenia is observed during acute infection with Trypanosoma cruzi, the parasitic protozoan
agent of American trypanosomiasis or Chagas’ disease. The parasite sheds trans-sialidase, an enzyme able to
mobilize the sialyl residues on cell surfaces, which is distributed in blood and is a virulence factor. Since the
sialic acid content on the platelet surface is crucial for determining the half-life of platelets in blood, we
examined the possible involvement of the parasite-derived enzyme in thrombocytopenia induction. We found
that a single intravenous injection of trans-sialidase into naı¨ve mice reduced the platelet count by 50%, a
transient effect that lasted as long as the enzyme remained in the blood. CD43/ mice were affected to a
similar extent. When green fluorescent protein-expressing platelets were treated in vitro with trans-sialidase,
their sialic acid content was reduced together with their life span, as determined after transfusion into naı¨ve
animals. No apparent deleterious effect on the bone marrow was observed. A central role for Kupffer cells in
the clearance of trans-sialidase-altered platelets was revealed after phagocyte depletion by administration of
clodronate-containing liposomes and splenectomy. Consistent with this, parasite strains known to exhibit more
trans-sialidase activity induced heavier thrombocytopenia. Finally, the passive transfer of a trans-sialidase-
neutralizing monoclonal antibody to infected animals prevented the clearance of transfused platelets. Results
reported here strongly support the hypothesis that the trans-sialidase is the virulence factor that, after
depleting the sialic acid content of platelets, induces the accelerated clearance of the platelets that leads to the
thrombocytopenia observed during acute Chagas’ disease.
Sialic acids are abundant nonreducing terminal sugars that
decorate mammalian glycolipids and glycoproteins. Because
they confer a negative charge that may dramatically change the
biologic properties of a given surface molecule, these sugar
residues have been implicated in many biological processes,
including cell-cell interactions, T-cell activation, and cellular
fate. Plasmatic glycoproteins and blood cell oligosaccharides
are highly sialylated, and the presence of the sugar is consid-
ered a key determinant for their survival in blood. In the case
of blood glycoproteins, the loss of sialyl residues tagged them
for destruction by liver cells via capture through the asialogly-
coprotein receptors. It is known that even a small decrease in
the sialic acid contents of platelet and red cell surfaces results
in a reduction in the life span (35), and in vitro treatment of
platelets with neuraminidase induces accelerated clearance
from the blood (23). In addition, injection of neuraminidases
into mammals also reduces the half-life of the platelets (10,
19). More importantly, cell surface sialylation is physiologically
decreased in several human diseases, resulting in faster re-
moval of platelets from the blood (1, 11, 17, 28). These findings
clearly indicate that sialic acid residues are involved in the
platelet half-life in blood.
Chagas’ disease is an endemic parasitosis that affects about
20 million people, and around 40 million people are at risk of
infection in the Americas (40). Trypanosoma cruzi, the caus-
ative agent, is a flagellated parasite with a complex life cycle
involving a hematophagous insect vector and a mammalian
host. During the acute phase of T. cruzi infection, several
hematologically abnormal parameters, including marked
thrombocytopenia, are observed (9). These alterations are
transient and can be prevented by trypanocidal drugs (9, 27),
but there is still no suitable molecular explanation for this. T.
cruzi is unable to synthesize sialic acids de novo (reviewed in
reference 16) but circumvents this limitation by expressing the
enzyme trans-sialidase (TS), which is able to directly transfer
(2,3)-linked sialyl residues among glycoproteins or glycolipids
(16, 34). TS is anchored to the membrane by glycosylphos-
phatidylinositol (2, 3) and is shed into the surrounding envi-
ronment, and it is detected in the blood of infected animals and
human patients during the acute stage of the infection (14, 24).
In the C terminus, the enzyme has tandem repetitive amino
acid units that allow it to persist in blood for at least 3 days (5,
6), which allows it to induce pathological disorders even far
from the infectious foci or to act on the blood cells (14, 30).
One of the biological activities is induction of apoptosis in
components of the immune system (25), including CD4
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CD8 thymocyte depletion inside the nurse cell complex (29).
Accordingly, virulent T. cruzi strains shed more TS activity
(33). Animals that survive infection and chronic Chagas’ dis-
ease patients elicit TS-neutralizing antibodies that are able to
inhibit TS enzymatic activity and limit the period in which the
distributed TS can systemically operate to the early steps of the
infectious process. Both the systemic activity restricted to the
acute phase and the ability of TS to alter the cell surface sialyl
residue distribution are characteristics that are expected for a
virulence factor that might be associated with the thrombocy-
topenia observed during this stage of the infection.
Here we report that the enzyme was able to remove sialic
acids from the platelet surface, leading to faster clearance of
the platelets from circulation. Furthermore, neutralization of
the circulating enzyme by passive transfer of a monoclonal
antibody to T. cruzi-infected animals prevented the clearance
of transferred tracer platelets. Our results support the hypoth-
esis that TS from T. cruzi is a virulence factor involved in the
thrombocytopenia observed early during the infection, which
provides a molecular explanation for the pathological findings.
MATERIALS AND METHODS
Mice. The BALB/cJ, C3H/HeJ, and C57BL/6J mouse strains and green fluo-
rescent protein (GFP)-expressing C57BL/6-Tg(ACTbEGFP)1Osb/J hemyzygous
transgenic male mice were originally obtained from The Jackson Labs (Bar
Harbor, Maine) and were bred in our facilities. B6.CD43null female mice back-
crossed eight times to C57BL/6 mice were generously provided by Anne I.
Sperling (University of Chicago) and crossed with GFP-expressing males. F1
CD43/ GFP-expressing males were backcrossed with CD43/ females, and
green males in the offspring were tested by PCR for the presence of the CD43
gene. A CD43/ GFP-expressing male was identified and crossed with
CD43/ females to produce CD43/ GFP-expressing mice. Animals that were
60 to 90 days old were used in this study except where indicated otherwise.
TS. Enzymatically active and inactive TS recombinant proteins that differed by
a single Tyr342His point mutation (12) were expressed in Escherichia coli DH5.
Proteins were induced with isopropyl -D-thiogalactopyranoside (Sigma Chem-
ical Co, St. Louis Mo.) and purified to homogeneity by immobilized metal affinity
chromatography through Ni2-charged Hi-Trap chelating columns (Amersham
Biosciences, Uppsala, Sweden), followed by ion-exchange chromatography with
a MonoQ column (Amersham Biosciences) as described previously (7). The His
tag was not removed from the recombinant enzyme. The specific activities of
recombinant and natural TS were around 3 to 4 U/nmol of TS protein (1 U of TS
activity was defined as the amount of enzyme that transferred 10 nmol of sialyl
residue to lactose in 1 min under standard conditions). TS was injected intrave-
nously (i.v.) at the doses indicated below for each experiment in 0.2 ml of
phosphate-buffered saline (PBS).
TS assay. The enzymatic activity of purified TS was assayed by measuring the
amount of sialic acid residue transferred from sialyllactose (Sigma) to [14C]lac-
tose (Amersham Biosciences) as previously described (24).
T. cruzi infection. Q501/3, a clone of the Tulahuen T. cruzi strain (lethal,
lineage II), and K-98, a clone of the CA-I T. cruzi strain (nonlethal, lineage I)
(33), were maintained by serial passage in mice. Animals were inoculated with
250 (Q501/3) or 50,000 (K-98) sanguineous trypomastigote forms by the intra-
peritoneal route.
Platelet purification. Peripheral blood was collected from the retroocular
plexus in polypropylene tubes containing 3.8% (wt/vol) sodium citrate (citrate/
blood ratio, 1:9). Platelet suspensions were obtained as described previously (21),
with slight modifications. Blood diluted 1:1 in PBS was overlaid onto a density
gradient (HISTOPAQUE-1083; Sigma). Platelets were recovered together with
the mononuclear cells, diluted 1:1 with PBS, and centrifuged at 140  g for 10
min. The supernatant was centrifuged for 10 min at 1,500  g, and the pellet was
resuspended in citrate-treated plasma previously centrifuged at 1,500  g (plate-
let-poor plasma) or PBS. All the manipulations were carried out at room tem-
perature. The number of platelets was determined by manual counting with a
Neubauer hemocytometer.
Sialic acid determination. Platelets (5 107 cells) were incubated with TS (0.1
to 6 g) for 1 h at room temperature in platelet-poor plasma. To determine the
(2,3)-linked sialic acid remaining in the surface, platelets were washed with PBS
and incubated with an excess (6 mU/l) of the specific neuraminidase from
Salmonella enterica serovar Typhimurium LT2 (New England Biolabs) in 150
mM NaCl—20 mM Tris-HCl (pH 6.8) for 1 h at 37°C. The platelets were
centrifuged at 1,500 g for 10 min, and the sialic acid content of the supernatant
was determined by the high-performance liquid chromatography–thiobarbituric
acid assay (31).
Irradiation of mice. Mice received a lethal dose (9 Gy) of gamma radiation,
and 72 h later the animals were inoculated i.v. with 0.5 or 5 g of TS. Platelet
counts were determined 18 h later.
Determination of in vivo survival of TS-treated platelets. GFP-expressing
platelets (5  107 cells) from a transgenic mouse were incubated with 0.1 to 2 g
of TS for 1 h at room temperature in platelet-poor plasma. The platelet suspen-
sion was diluted in 0.2 ml of PBS and injected i.v. Eighteen hours after transfu-
sion, green platelets were counted by using an epifluorescence microscope
(Eclipse 600; Nikon, Tokyo, Japan).
Professional phagocyte depletion. Kupffer cells and other macrophages were
depleted by injection of liposome-encapsulated clodronate (dichloromethylene
bisphosphonate) (4, 41, 42). Animals received 250 l of a liposome suspension
intraperitoneally 24 h before administration of 10 g of TS. The clodronate was
a gift from Roche Diagnostics GmbH, Mannheim, Germany. Phosphatidylcho-
line (LIPOID E PC) was obtained from Lipoid GmbH, Ludwigshafen, Germany,
and cholesterol was obtained from Sigma.
Monoclonal antibody administration. A TS-neutralizing mouse monoclonal
antibody (immunoglobulin G2a) was recently obtained in our lab (T. Pitcovsky
R. Muia´, and O. Campetella, unpublished data), and ascitic fluid (neutralizing
titer, 1:80,000, as determined by a TS inhibition assay [26]) was obtained from
animals inoculated with hybridoma. In three separate experiments, mice received
a single 50-l dose of ascitic fluid intraperitoneally on day 10, 11 or 12 after
infection, when the parasitemia values were 1  105 to 8.5  105 parasites/ml,
and 24 h later 1  108 to 2  108 fluorescent platelets were transfused. The
remaining fluorescent platelet count was determined 18 h later. Sera from pas-
sively transferred animals were able to neutralize 100% of added TS under
standard conditions (26).
Splenectomy. Animals (30 to 45 days old) were splenectomized under chloral
hydrate (Sigma) anesthesia and left to recover for at least 2 weeks before further
analysis.
Statistical analysis. Student’s t test was employed.
RESULTS
TS is able to reduce the life span of platelets. Several he-
matological alterations, including strong thrombocytopenia,
occur during the acute phase of Chagas’ disease (9, 27), the
period in which the TS is detected in the circulation. To de-
termine if TS is involved in the induction of thrombocytopenia,
different amounts of enzyme (1 to 10 g) were injected intra-
venously (Fig. 1A). A strong reduction (around 50%) in the
normal platelet count was observed 18 h after TS injection
(Fig. 1A). This effect was found to be transient and dose
dependent, and a significant reduction was observed even
when 1 g of enzyme was administered. No effect was observed
when enzymatically inactive TS was given.
TS has the ability to disseminate systemically through the
bloodstream, and the blood and bone marrow are the two main
sites where the enzyme may act to reduce the platelet count.
From previous assays it seemed that TS was able to affect the
platelets in blood. No obvious cytological damage was ob-
served in bone marrow samples taken from the mice inocu-
lated with TS (data not shown). Furthermore, approximately
100% increases in the megakariocyte counts both in the bone
marrow and in the spleen were observed 3 days after a single
TS injection (10 g), supporting the hypothesis that the bone
marrow was essentially unaltered. These findings were also
supported by the recovery of the normal platelet count (Fig.
1A). To further test the effect that the enzyme had on the
circulating platelets, lethally irradiated mice were inoculated
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with a unique dose of TS. These bone marrow-depleted mice
exhibited a strong reduction in the platelet count (Fig. 1B),
supporting the hypothesis that TS was able to act on platelets
in the circulation.
Platelet surface sialic acid content is reduced by TS. Surface
sialic acid is critical for the presence of platelets, red blood
cells, and glycoproteins in the circulation (23, 35). Therefore,
the surface sialic acid content of platelets was quantified after
TS treatment to verify the ability of this virulence factor to
affect the platelet life span and to produce thrombocytopenia
by direct action on the platelets. To do this, platelets were
incubated with different amounts of TS (0 to 6 g) (Fig. 2), and
the remaining surface (2,3)-linked sialic acid was quantified.
A significant reduction in the sialic acid content was observed
after TS treatment even when as little as 0.5 g of the enzyme
was used (Fig. 2A). To test whether treatment with these
amounts of TS could alter the platelet life span, GFP-express-
ing platelets were assayed. When tracer platelets were treated
with 0.5 g of TS, they were rapidly removed from the circu-
lation after administration into naı¨ve mice (Fig. 2B). The re-
sults of these experiments clearly supported the hypothesis that
TS is able to remove sialic acid from the cell surface and that
this activity is associated with the reduction in the platelet life
span.
Leukosialin is not critical for platelet depletion by TS. CD43
(leukosialin, sialophorin) is a heavy sialylated mucin that ac-
counts for about 20 to 25% of the total surface area of white
cells and is a substrate of TS (37). Therefore, to analyze its
possible involvement, CD43 knockout (KO) mice were as-
sayed. The blood platelet count and the amount of sialic acid
in these KO animals were indistinguishable from the values for
CD43/ mice. Administration of TS to KO animals induced
thrombocytopenia to an extent that was similar to the extent in
CD43/ mice. The half-life of the CD43/ platelets was
determined by passive transfer of CD43/ GFP-expressing
platelets to both CD43 KO and CD43/ mice and was found
to be similar to that of control CD43/ GFP-expressing plate-
lets. Since no CD43 was expressed, it seems that the other
sialylated glycoconjugates (i.e., glycoproteins, gangliosides)
compensated for the total sialic acid content required for the
platelets to remain in the blood, and they also were suitable
targets for the enzyme.
Kupffer cells are responsible for the clearance of TS-altered
platelets from the blood. Beyond the small number of platelets
consumed daily to maintain hemostasis, the spleen and liver
are the organs where sequestration of damaged, altered, or
aged platelets occurs. It has been postulated that the decre-
ment of sialic acid from the surface of the platelets results in
recognition of these cells as aged or foreign by the reticuloen-
dothelial system (18, 23). As a first approach to assay the
involvement of this compartment in the removal of the TS-
altered platelets, splenectomized mice were tested. The ani-
mals received a high dose of TS (10 g), and there was no
difference in the reduction of blood platelet counts after injec-
tion between naı¨ve and splenectomized mice (compare Fig. 1
and 3A). To further analyze this compartment, we employed
GFP-expressing platelets treated with TS and then transfused
them to splenectomized and normal mice. In agreement with
data shown in Fig. 3A, treated fluorescent platelets were rap-
idly removed in splenectomized mice, as they were in normal
FIG. 1. TS reduces the life span of platelets. (A) Administration of TS induces transient thrombocytopenia. C3H/HeJ mice were inoculated
intravenously with different amounts of recombinant TS. The platelet counts and the remaining TS activity in the blood are expressed as
percentages. The P values for comparisons with data obtained on day 0 or on day 6 or 7 were as follows: for platelet counts on days 1, 2, and 3
in the 10-g dose group, P  0.002; for platelet counts on days 1, 2, and 3 in the 5-g dose group, P  0.001; for platelet counts on days 1, 2, and
3 in the 2-g dose group, P 0.001; and for platelet counts on days 1 and 2 in the 1-g dose group, P 0.05. (B) TS acts on the circulating platelets.
C3H/HeJ mice were lethally irradiated, and then different amounts of TS were given intravenously. Platelet counts were determined 18 h later.
For a comparison of the group that received no TS and the group that received 5 g of TS, the P value was 0.01. Each group contained at least
three animals.
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receptor animals (Fig. 3B). These results indicated that the
spleen is not the main organ for TS-altered platelet removal.
To analyze other components that might be involved, all the
professional phagocytes, including Kupffer cells, were de-
pleted. Mice were treated with liposome-encapsulated clodr-
onate, and 24 h later a high dose (10 g) of TS was adminis-
tered (4, 22, 41, 42). In spite of the fact that a similar strong
treatment induced the loss of a great number of platelets, as
shown in Fig. 1A, only a minimal reduction in the platelet
count was observed after TS was injected into phagocyte-de-
pleted mice (Fig. 3C). In addition, this small reduction could
be explained by the formation and sequestration of platelet-
liposome microaggregates (32). Together with the findings ob-
tained with splenectomized mice, these results support the
hypothesis that the Kupffer cells play a central role as scaven-
gers for the TS-altered platelets.
TS is associated with the thrombocytopenia observed during
T. cruzi infection. Thrombocytopenia is described as one of the
more relevant hematological findings during early T. cruzi in-
fection and correlates well with the detection of TS activity in
blood, which indirectly supports the hypothesis that it partici-
pates in the platelet count reduction process.
Two main possible effects have to be considered as effects
that are involved in the induction of thrombocytopenia during
infection, disabling of the bone marrow and alteration of the
circulating platelets that leads to their destruction. To deter-
mine whether during infection platelets are altered in a way
that leads to their clearance, unaltered GFP-expressing plate-
lets were transfused to T. cruzi-infected animals. As shown in
Fig. 4B, green platelets disappeared from the blood at a higher
rate in infected animals than in naı¨ve animals. This finding
demonstrated that during infection, the platelet life span is
shortened independent of a possible effect of the inflammatory
activities derived from the infectious process on the bone mar-
row.
Recently, it was shown that TS activity is differentially ex-
pressed in the main T. cruzi lineages and is shed into the milieu
at higher rates with T. cruzi lineage II than with T. cruzi lineage
I (33). Circulating TS activity is detected only during the acute
phase in mice infected with T. cruzi lineage II since in mice
infected with T. cruzi lineage I strains neutralizing antibodies
are developed (33). Therefore, it can be postulated that throm-
bocytopenia might be related to this differential expression. To
test this hypothesis, mice were infected with T. cruzi strains
that were representatives of the two lineages, and the platelet
counts were determined. The K-98 parasites (T. cruzi lineage I
representative) induced only transient thrombocytopenia, in
contrast to the strong platelet depletion observed in the ani-
mals infected with Q501/3 (T. cruzi lineage II) (Fig. 4A).
To directly test whether TS is actually associated with the
circulating platelet depletion in acute Chagas’ disease, the en-
zymatic activity during T. cruzi acute infection was neutralized.
For this purpose, mice were infected with Q501/3 (a T. cruzi
lineage II strain) and passively transfused with a unique dose
of a TS-neutralizing monoclonal antibody at days 10 to 12
postinfection. One day later the animals were transfused with
untreated GFP-expressing platelets. In the infected mice in
which the T. cruzi-derived TS activity was neutralized, fluores-
cent platelets were cleared at a rate that was lower than the
rate in the mice that received unrelated antibodies (Fig. 4B).
These results indicate that the TS activity is directly involved in
the thrombocytopenia induced by T. cruzi in a mammalian
infection by altering the circulating platelets.
DISCUSSION
During experimental infection of mice with T. cruzi, strong
thrombocytopenia is observed (9, 27), suggesting the possible
involvement of TS from the parasite that alters the platelet
surface sialic acid content by acting as a neuraminidase (13).
From the results reported here we concluded that the capacity
of this blood-borne virulence factor to alter the sialylation of
the platelet surface directly affects the life span of platelets. It
can be postulated that the constant impact of the shed TS, even
FIG. 2. Platelet desialylation by TS correlates with a reduction in
the life span. (A) Platelets (5  107 cells) were treated in vitro with
different amounts of TS, and the released sialic acid was quantified.
For all groups that received 0.5 g of TS or more, the data were
statistically significant (starting at P  0.05 for the 0.5-g group) for
comparisons with the untreated control. (B) GFP-expressing platelets
were treated in vitro with different amounts of TS and then transferred
to naı¨ve animals. Green platelet counts were determined 18 h later by
fluorescence microscopy. The results are expressed as percentages of
the remaining green platelets; 100% was defined as the value for
controls that received platelets not treated with TS. The values for
groups that were treated with 0.5 and 2 g of TS were found to be
statistically significantly different from the other values (P  0.005).
Each group contained at least three animals.
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in small amounts, on the platelets finally leads to the develop-
ment of the thrombocytopenia observed in the animals. How-
ever, during the infection, other molecules, either molecules
from the parasite or molecules derived from the immune re-
sponse against the infection, like cytokines or other inflamma-
tory products, might also collaborate in this process. Neverthe-
less, clearance of transferred platelets was prevented in
infected animals by passive transfer of a monoclonal neutral-
izing antibody, which provided strong evidence that TS is in-
volved in the thrombocytopenia that is induced. Platelets were
postulated to be capable of inducing parasite lysis after inter-
action via their C3b receptor (38), and a direct role for plate-
lets in in vivo parasite clearance (but only in the presence of
antibodies) was also suggested (36, 39). Based on this line of
evidence, TS might participate in prevention of parasite elim-
ination during the acute phase of the infection by reducing the
amount of platelets or by altering the platelets that interact
with the parasite.
The bone marrow becomes depleted during acute infection
with virulent T. cruzi strains (27). Although a possible effect of
prolonged exposure to TS, as happens during infection, cannot
be disregarded, from the evidence at hand it seems that the
destruction of this tissue is more likely to be due to the immune
response or to other parasite-derived factors. No obvious evi-
dence of morphological alterations of the bone marrow cells
was found after a single injection of the enzyme, and the
thrombopoiesis capacity remained unaltered, as suggested by
the recovery of normal platelet counts when the TS activity
disappeared. This is consistent with the finding that in surviv-
ing animals the normal platelet count recovers when the par-
asitemia is controlled (9). Thrombopoietin is constitutively
produced by the liver and kidneys, but its actual activity with
precursor cells is regulated by the number of circulating plate-
lets because of the expression of the corresponding receptor
(c-Mpl) on the surface, which tunes the activity (20, 43). There-
fore, the observed increase in the number of megakariocytes in
both the bone marrow and the spleen after TS injection seems
to accompany the thrombocytopenia induced by the platelet
destruction instead of being related to a possible direct effect
of the TS on the earlier precursor cells.
TS is in fact a modified sialidase that has acquired the ability
to transfer the sialyl residue to a -linked terminal galactose
instead to water (hydrolysis) (7, 8). Although a possible role in
redistribution of the sialyl residues among the surface glyco-
conjugates cannot be disregarded, the loss of sialyl residues
from the platelets after TS treatment strongly supports the
hypothesis that their increased clearance is due to the (2,3)-
neuraminidase activity of the enzyme. As shown in Fig. 2,
depletion of (2,3)-linked sialic acid occurs at a level that is
able to alter the life span of platelets in blood (18). It should be
stressed that the sialyl residues linked by (2,3) linkages, but
not the residues linked by (2,6) linkages, are the residues that
are critical in determining the half-life of platelets and seric
factors (15) and that the (2,3) linkage is the linkage with
specificity or a preferred configuration for almost all of the
pathogen-derived sialidases, suggesting a general target for
these virulence factors.
Desialylation is known to lead to sequestration of platelets
from the blood by the reticuloendothelial system. Here we
determined that the spleen is not critical in the destruction of
TS-altered platelets, and our findings strongly support involve-
ment of the Kupffer cells in this process instead. Similar ex-
perimental approaches recently resulted in determination of
the involvement of Kupffer cells in the clearance of erythro-
cytes deficient in glycosyl phosphatidylinositol-linked proteins
(22). In this regard it should be pointed out that strong throm-
bocytopenia also occurs during infection of splenectomized
mice that show progressive platelet depletion, as well as in
FIG. 3. Kupffer cells are involved in the clearance of TS-altered platelets. (A) Splenectomized BALB/cJ mice were inoculated with 10 g of
TS i.v. The platelet counts and the remaining TS activity in the blood are expressed as percentages. The P values for comparisons with data
obtained on days 0 and 7 were as follows: for platelet counts on days 1, 2, and 3, P  0.001; and for platelet counts on day 4, P  0.05.
(B) GFP-expressing platelets were transferred after in vitro TS treatment (2 g) to either normal or splenectomized (Spx) animals. Green platelet
counts were determined 18 h later by fluorescence microscopy. For a comparison of the group that received TS and the group that did not receive
TS, the P value was0.005. (C) Mice were treated with liposome-encapsulated clodronate 24 h before administration of TS (10 g). Platelet counts
determined 18 h after TS administration are expressed as percentages of the value for naı¨ve animals. Ctl, control animals that received TS; Lip,
liposome-treated animals that received TS. For a comparison of the control animals and the liposome-treated animals, the P value was0.01. Each
group contained at least four animals.
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infected control animals (9). The fact that a parasite-derived
virulence factor is involved is further supported by our findings
obtained with parasites that were representative of the main T.
cruzi lineages (Fig. 4), which showed that a nonlethal strain (T.
cruzi lineage I) that expressed or shed smaller amounts of TS
was unable to induce persistent thrombocytopenia, although
comparable levels of parasitemia were reached. Together with
the TS neutralization assay results, these results indicate that
TS is the virulence factor that causes the thrombocytopenia
during the acute phase of Chagas’ disease.
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